Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease

Recruiting now

Conditions studied: Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Obesity and Obesity-related Medical Conditions

In brief

A generic screening study to establish structural and/or functional baselines of specific organs.

Key facts

Study ID

NCT04873258

Run by

Richmond Research Institute

People needed

2000

Starts

2019-09-27

Expected to finish

2027-12-31

Last updated by the study team

2025-07-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.
• Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.
• An understanding, ability and willingness to fully comply with project procedures and restrictions.
• For PART B only:
• With a known history of MASLD as evidenced either of:
• GP diagnosis on HCF
• Documented Fibroscan or liver US demonstrating MASLD

You may not qualify if…

• Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)
• Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)
• Alcohol consumption >30 units per week
• An Implanted cardiac devices

Where it is running

• Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge — London, London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.